This study is testing if a combination of odronextamab and lenalidomide is safe and works better than rituximab and lenalidomide for adults with follicular lymphoma (FL) or marginal zone lymphoma (MZL). These are types of non-Hodgkin's lymphoma that have either come back after treatment (relapsed) or didn't respond to previous treatment (refractory). Odronextamab is an immunotherapy, a type of monoclonal antibody. The study aims to find the right dose of odronextamab and see how well it works and what side effects it might cause. You could be eligible if you are 18 or older and have FL or MZL that has relapsed or is refractory after at least one prior treatment.

Study design

This study plans to enroll 470 participants and has two parts: Part 1 is not randomized, and Part 2 is randomized and controlled.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track side effects for up to 2 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.